OncoMatch/Clinical Trials/NCT07026149

Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer

Is NCT07026149 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Apatinib+Camrelizumab+SOX for gastric and gastroesophageal junction (gej) adenocarcinoma.

Phase 2RecruitingRuijin HospitalNCT07026149Data as of May 2026

Treatment: Apatinib+Camrelizumab+SOX — The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Esophageal Carcinoma

Disease stage

Required: Stage T3-4N+M0

Has previously untreated localized gastric or GEJ adenocarcinoma as defined by T3-4N+M0

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Has adequate organ function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify